☰

Colorectal Cancer Clinical Trials

Last reviewed: November 15, 2026

Start with colon versus rectal cancer, stage, surgery status, exact biomarker results and prior treatment. A study before surgery, after surgery or after metastatic treatment may have very different entry requirements.

Answer a few questions to find clinical trials matched to your specific Colorectal Cancer situation.

A thorough search takes ~15 minutes — we'll email your results. No sign-up.

Find matching trials →

Choose the Treatment Setting First

Current Clinical Trial Landscape

Registry snapshot, November 15, 2026: the worldwide ClinicalTrials.gov search for Colorectal Cancer, interventional studies and Recruiting status returned 1,182 records. This is a broad result, not 1,182 personally suitable trials. Open the filtered registry search.

Research areas include biomarker-selected treatment, immunotherapy combinations, ADCs, organ preservation, postoperative treatment and liver-directed approaches. Categories overlap; fresh class-specific totals are not claimed.

Biomarkers and Treatment History to Bring

Approved Treatment and Trial Enrollment Are Different

Selected U.S. examples illustrate why setting and biomarkers matter:

These are selected examples, not a complete treatment recommendation. Discuss current local labels and standard-care alternatives with your oncology team.

What ctDNA-Guided Research Does—and Does Not—Establish

Postoperative ctDNA can help study recurrence risk, but risk prediction and proof that changing treatment improves outcomes are different questions. Test timing, assay sensitivity, stage and pathological risk matter. Do not infer that every ctDNA-positive patient benefits from escalation or every negative patient can safely omit treatment. The studies below test defined strategies; follow the study protocol and oncology advice.

ASCO's 2026 ctDNA guideline describes evidence limitations and does not make a general recommendation for recurrence monitoring. This page does not recommend stopping, escalating or omitting treatment on a ctDNA result alone.

Have your stage, biomarker reports and treatment history ready?

Find Matching Trials

Selected Trials by Biomarker and Setting

All 49 cited records were checked November 15, 2026: 39 recruiting, seven not yet recruiting, two active but not recruiting and one unknown. Non-enrolling and unknown-status examples are separated at the end. Each example has its phase and recruitment label; site and cohort availability still need confirmation.

dMMR/MSI-H rectal and colon studies around surgery

Rectal organ preservation and other local/neoadjuvant studies

MSS/pMMR advanced disease: first-line immunotherapy combinations

MSS/pMMR previously treated advanced disease

KRAS G12C first-line studies

RAS/BRAF wild-type EGFR-directed studies

BRAF V600 basket study

HER2-positive metastatic disease: first-line research

HER2-selected previously treated disease and exploratory cohorts

Previously treated metastatic disease: ADC research

Postoperative ctDNA-guided research

Limited metastatic disease, liver-directed treatment and dosing research

Not yet recruiting

Active, not recruiting

Recruitment unknown: confirm before considering enrollment

Not yet recruiting means new enrollment has not started; active, not recruiting means treatment/follow-up may continue without new enrollment. Unknown status requires current confirmation and must not be treated as open.

Frequently Asked Questions

How do I find colorectal cancer trials for my biomarkers?

Start with colon versus rectal cancer, stage and resectability, MSI/MMR, exact RAS/BRAF and HER2 findings, prior treatment and location. ClinTrialFinder suggests studies for discussion; the study team confirms eligibility and availability.

How many colorectal cancer trials are recruiting?

The November 15, 2026 worldwide ClinicalTrials.gov query for Colorectal Cancer, interventional studies and Recruiting status returned 1,182 records. This broad search is not a personalized count. Of the 49 selected records here, 39 were recruiting; nine were not open to new enrollment and one had unknown status.

Do MSI-H/dMMR and MSS/pMMR use the same trials?

Often not. Some immunotherapy protocols require MSI-H/dMMR, while others select MSS/pMMR and exclude dMMR. Stage and colon versus rectal location also matter. TNTi (NCT06229041), for example, excludes MSI-H/dMMR despite studying immunotherapy in rectal cancer.

Can a negative ctDNA test mean I can skip chemotherapy?

Not on its own. A negative ctDNA result can miss residual disease, and treatment decisions also depend on stage, pathology, prior treatment, test timing and the evidence for a specific strategy. The postoperative trials here test defined escalation or de-escalation approaches; discuss treatment with your oncology team.

Which HER2-positive metastatic colorectal trials are first-line versus refractory?

MOUNTAINEER-03 (NCT05253651) studies tucatinib/trastuzumab/mFOLFOX6 first-line. JSKN003 (NCT07384377) and TQB2102 (NCT07483684) require prior chemotherapy failure and were not yet recruiting on November 15; they are not first-line options. IHC/ISH thresholds, RAS/BRAF results and prior HER2 exposure differ by protocol.

Can organ-preservation trials guarantee that rectal surgery is avoided?

No. Studies use different biomarker, stage and response requirements. Clinical complete response and close surveillance are important in nonoperative approaches, and further surgery or radiation may still be needed. Colon protocols should not be substituted for rectal protocols.

Find Colorectal Cancer Trials Matched to Your Situation

Enter your MSI/MMR status, RAS/BRAF mutations, and treatment history to get AI-matched results in minutes.

Find Matching Trials